

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

APRIA HEALTHCARE GROUP INC
Form 10-Q
August 14, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the period ended June 30, 2002

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-14316

APRIA HEALTHCARE GROUP INC.
(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

33-0488566
(I.R.S. Employer
Identification Number)

26220 ENTERPRISE COURT, LAKE FOREST, CA
(Address of principal executive offices)

92630
(Zip Code)

Registrant's telephone number, including area code: (949) 639-2000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No

There were 54,700,148 shares of common stock, \$.001 par value, outstanding at August 9, 2002.

APRIA HEALTHCARE GROUP INC.

FORM 10-Q

FOR THE PERIOD ENDED JUNE 30, 2002

PART I. FINANCIAL INFORMATION

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

- Item 1. Financial Statements (unaudited)
- Condensed Consolidated Balance Sheets
 - Condensed Consolidated Income Statements
 - Condensed Consolidated Statements of Cash Flows
 - Notes to Condensed Consolidated Financial Statements
- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
- Item 3. Quantitative and Qualitative Disclosures About Market Risk

PART II. OTHER INFORMATION

- Item 1. Legal Proceedings
- Item 2. Changes in Securities
- Item 3. Defaults Upon Senior Securities
- Item 4. Submission of Matters to a Vote of Security Holders
- Item 5. Other Information
- Item 6. Exhibits and Reports on Form 8-K

SIGNATURES

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

APRIA HEALTHCARE GROUP INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(DOLLARS IN THOUSANDS, EXCEPT SHARE DATA)	JUNE 30, 2002	DECEMBER 31, 2001

ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 17,114	\$ 9,114
Accounts receivable, less allowance for doubtful accounts of \$32,068 and \$32,073 at June 30, 2002 and December 31, 2001, respectively	176,976	162,976
Inventories, net	23,737	25,737
Deferred income taxes	30,073	33,073
Prepaid expenses and other current assets	10,743	10,743
	258,643	239,643
TOTAL CURRENT ASSETS		
PATIENT SERVICE EQUIPMENT, less accumulated depreciation of \$358,604 and \$342,010 at June 30, 2002 and December 31, 2001, respectively	168,859	165,859
PROPERTY, EQUIPMENT AND IMPROVEMENTS, NET	52,325	47,325
DEFERRED INCOME TAXES	19,893	37,893
GOODWILL, NET	208,469	193,469

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

INTANGIBLE ASSETS, NET	4,565	4
OTHER ASSETS	6,981	7
	-----	-----
	\$ 719,735	\$ 695
	=====	=====

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES		
Accounts payable	\$ 55,045	\$ 71
Accrued payroll and related taxes and benefits	30,138	33
Accrued insurance	11,762	10
Income taxes payable	9,856	9
Other accrued liabilities	33,837	34
Current portion of long-term debt	28,053	15
	-----	-----
TOTAL CURRENT LIABILITIES	168,691	174
LONG-TERM DEBT, net of current portion	261,503	278
COMMITMENTS AND CONTINGENCIES (Note I)		
STOCKHOLDERS' EQUITY		
Preferred stock, \$.001 par value: 10,000,000 shares authorized; none issued	-	
Common stock, \$.001 par value: 150,000,000 shares authorized; 55,967,018 and 54,690,267 shares issued at June 30, 2002 and December 31, 2001, respectively; 54,876,118 and 54,604,167 outstanding at June 30, 2002 and December 31, 2001, respectively	56	
Additional paid-in capital	387,877	368
Treasury stock, at cost; 1,090,900 and 86,100 shares at June 30, 2002 and December 31, 2001, respectively	(22,741)	
Accumulated deficit	(75,401)	(124)
Accumulated other comprehensive (loss) income	(250)	
	-----	-----
	289,541	242
	-----	-----
	\$ 719,735	\$ 695
	=====	=====

See notes to condensed consolidated financial statements.

APRIA HEALTHCARE GROUP INC.

CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)

(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)	THREE MONTHS ENDED JUNE 30,		SIX MONTHS EN JUNE 30,	
	2002	2001	2002	2001
Net revenues	\$310,425	\$283,480	\$611,770	\$554
Costs and expenses:				
Cost of net revenues:				

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

Product and supply costs	56,751	49,775	111,913	101
Patient service equipment depreciation	24,425	22,477	47,842	43
Nursing services	228	306	499	
Other	3,079	3,017	6,348	6
	-----	-----	-----	-----
TOTAL COST OF NET REVENUES	84,483	75,575	166,602	151
Selling, distribution and administrative	167,913	158,097	334,021	306
Provision for doubtful accounts	11,547	11,069	23,058	19
Amortization of goodwill and intangible assets	665	3,126	1,336	5
	-----	-----	-----	-----
TOTAL COSTS AND EXPENSES	264,608	247,867	525,017	483
OPERATING INCOME	45,817	35,613	86,753	71
Interest expense, net	3,965	8,027	8,109	16
	-----	-----	-----	-----
INCOME BEFORE TAXES	41,852	27,586	78,644	54
Income tax expense	15,694	10,339	29,491	20
	-----	-----	-----	-----
NET INCOME	\$ 26,158	\$ 17,247	\$ 49,153	\$ 34
	=====	=====	=====	=====
Basic net income per common share	\$ 0.48	\$ 0.32	\$ 0.90	\$
	=====	=====	=====	=====
Diluted net income per common share	\$ 0.47	\$ 0.31	\$ 0.89	\$
	=====	=====	=====	=====

See notes to condensed consolidated financial statements.

APRIA HEALTHCARE GROUP INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	SIX MONTHS JUNE 30	

(DOLLARS IN THOUSANDS)	2002	

OPERATING ACTIVITIES		
Net income	\$ 49,153	\$
Items included in net income not requiring cash:		
Provision for doubtful accounts	23,058	
Depreciation and amortization	57,351	
Amortization of deferred debt issuance costs	644	
Deferred income taxes and other	21,879	
Changes in operating assets and liabilities, exclusive of effects of acquisitions:		
Accounts receivable	(38,252)	
Inventories, net	1,439	
Prepaid expenses and other assets	(657)	
Accounts payable, exclusive of outstanding checks	(8,928)	
Accrued payroll and related taxes and benefits	(3,769)	
Income taxes payable	8,125	
Accrued expenses	(2,304)	

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

NET CASH PROVIDED BY OPERATING ACTIVITIES	107,739
INVESTING ACTIVITIES	
Purchases of patient service equipment and property, equipment and improvements, exclusive of effects of acquisitions	(57,105)
Proceeds from disposition of assets	144
Cash paid for acquisitions, including payments of deferred consideration	(15,689)
NET CASH USED IN INVESTING ACTIVITIES	(72,650)
FINANCING ACTIVITIES	
Proceeds from revolving credit facilities	120,700
Payments on revolving credit facilities	(128,500)
Payments on term loans	(875)
Payments on other long-term debt	(1,481)
Outstanding checks included in accounts payable	(7,225)
Capitalized debt issuance costs, net	(659)
Repurchases of common stock	(21,780)
Issuances of common stock	12,486
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(27,334)
NET INCREASE IN CASH AND CASH EQUIVALENTS	7,755
Cash and cash equivalents at beginning of period	9,359
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 17,114

See notes to condensed consolidated financial statements.

APRIA HEALTHCARE GROUP INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE A - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Apria Healthcare Group Inc. ("Apria" or "the company") and its subsidiaries. Intercompany transactions and accounts have been eliminated.

In the opinion of management, all adjustments, consisting of normal recurring accruals necessary for a fair presentation of the results of operations for the interim periods presented, have been reflected herein. The unaudited results of operations for interim periods are not necessarily indicative of the results to be expected for the entire year. For further information, refer to the consolidated financial statements and footnotes thereto for the year ended December 31, 2001, included in the company's 2001 Form 10-K.

NOTE B - RECLASSIFICATIONS, ACCOUNTING ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS

Reclassifications: Certain amounts from prior periods have been reclassified to conform to the current period presentation.

Use of Accounting Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

America requires management to make assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Recent Accounting Pronouncements: Effective January 1, 2002, Apria adopted Statement of Financial Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets" in its entirety. SFAS No. 142 addresses the financial accounting and reporting for goodwill and other intangible assets. The statement provides that goodwill or other intangible assets with indefinite lives will no longer be amortized, but shall be tested for impairment annually, or more frequently if circumstances indicate potential impairment. The effect of adoption of SFAS No. 142 on the consolidated financial statements is shown in Note E - Goodwill and Intangible Assets.

Effective January 1, 2002, Apria was required to adopt SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." This statement supercedes SFAS No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of" and amends other guidance related to the accounting and reporting of long-lived assets. SFAS No. 144 requires that one accounting model be used for long-lived assets to be disposed of by sale. Discontinued operations will be measured similarly to other long-lived assets classified as held for sale at the lower of its carrying amount or fair value less cost to sell. Future operating losses will no longer be recognized before they occur. SFAS No. 144 also broadens the presentation of discontinued operations to include a component of an entity when operations and cash flows can be clearly distinguished, and establishes criteria to determine when a long-lived asset is held for sale. Adoption of this statement did not have a material effect on Apria's consolidated financial statements.

NOTE C - REVENUE RECOGNITION AND CONCENTRATION OF CREDIT RISK

Net revenues are recognized on the date services and related products are provided to patients and are recorded at amounts expected to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare and Medicaid. Approximately 33% of the company's revenues are reimbursed under arrangements with Medicare and Medicaid. No other third-party payor group represents 10% or more of the company's revenues. The majority of the company's revenues are derived from fees charged for patient care under fee-for-service arrangements. Revenues derived from capitation arrangements represent less than 10% of total net revenues.

Due to the nature of the industry and the reimbursement environment in which Apria operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review.

Management performs various analyses to evaluate the net realizable value of accounts receivable. Specifically, management considers historical realization data, accounts receivable aging trends, other operating trends and relevant business conditions. Management also performs focused reviews of certain large and/or problematic payors. Because of continuing changes in the healthcare industry and third-party reimbursement, management's estimates may change from time to time, which could have a material impact on operations and cash flows.

Accounts receivable are reduced by an allowance for doubtful accounts which provides for those accounts from which payment is not expected to be received,

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

although services were provided and revenue was earned.

NOTE D - BUSINESS COMBINATIONS

Apria periodically makes acquisitions of complementary businesses in specific geographic markets. The transactions are accounted for as purchases and the results of operations of the acquired companies are included in the accompanying consolidated income statements from the date of acquisition. During the six-month period ended June 30, 2002, cash paid for acquisitions was \$15,689,000, which included amounts deferred from prior years of \$1,212,000. At June 30, 2002, outstanding deferred consideration totaled \$5,820,000.

For the acquisitions that were completed during the six-month period ended June 30, 2002, \$15,750,000 was allocated to goodwill, including amounts not yet paid, \$581,000 to intangible assets and \$1,725,000 to patient service equipment.

NOTE E - GOODWILL AND INTANGIBLE ASSETS

In July 2001, Apria adopted SFAS No. 141, "Business Combinations", which requires that the purchase method of accounting be applied to all business combinations completed after June 30, 2001 and which also addresses the criteria for initial recognition of intangible assets and goodwill. Effective January 1, 2002, the company adopted SFAS No. 142, "Goodwill and Other Intangible Assets", in its entirety. SFAS No. 142 addresses the financial accounting and reporting for goodwill and other intangible assets. The statement provides that goodwill and other intangible assets with indefinite lives will no longer be amortized, but shall be tested for impairment annually, or more frequently if circumstances indicate potential impairment. If the carrying value of goodwill or an intangible asset exceeds its fair value, an impairment loss shall be recognized.

In the year of adoption, SFAS No. 142 requires that a transitional goodwill impairment test be performed and that the results be measured as of the beginning of the year. The test is conducted at a "reporting unit" level and compares each reporting unit's fair value to its carrying value. The company has determined that its geographic regions are reporting units under SFAS No. 142. The measurement of fair value for each region was based on an evaluation of future discounted cash flows and was further tested using a multiple of earnings approach. The transitional test, which has been completed, indicated that no impairment exists and, accordingly, no loss was recognized.

In conjunction with the transitional impairment test and based on the criteria established in SFAS No. 141, management reviewed the useful lives and the amounts previously recorded for intangible assets and determined that no adjustments were necessary.

The following table sets forth the reconciliation of net income and earnings per share as adjusted for the non-amortization provisions of SFAS No. 142:

(IN THOUSANDS, EXCEPT PER SHARE DATA)	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2002	2001	2002	2001
Reported net income	\$ 26,158	\$ 17,247	\$ 49,153	\$ 34,3
Add: goodwill amortization, net of taxes...	-	1,556	-	2,9
Adjusted net income	\$ 26,158	\$ 18,803	\$ 49,153	\$ 37,2

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

	=====	=====	=====	=====
BASIC INCOME PER COMMON SHARE:				
Reported net income	\$ 0.48	\$ 0.32	\$ 0.90	\$ 0.00
Goodwill amortization, net of taxes....	-	0.03	-	0.00
	-----	-----	-----	-----
Adjusted net income	\$ 0.48	\$ 0.35	\$ 0.90	\$ 0.00
	=====	=====	=====	=====
DILUTED INCOME PER COMMON SHARE:				
Reported net income	\$ 0.47	\$ 0.31	\$ 0.89	\$ 0.00
Goodwill amortization, net of taxes....	-	0.03	-	0.00
	-----	-----	-----	-----
Adjusted net income	\$ 0.47	\$ 0.34	\$ 0.89	\$ 0.00
	=====	=====	=====	=====

Goodwill and intangible assets consist of the following:

(DOLLARS IN THOUSANDS)	JUNE 30, 2002
-----	-----
Goodwill from business combinations completed on or before June 30, 2001.....	\$203,070
Less accumulated amortization.....	(48,490)

	154,580
Goodwill from business combinations completed after June 30, 2001.....	53,880

	\$208,460
	=====
Intangible assets subject to amortization, comprised of covenants not to compete.....	\$ 17,020
Less accumulated amortization.....	(12,450)

	\$ 4,570
	=====

For the six months ended June 30, 2002, the net change in the carrying amount of goodwill of \$15,011,000 is the result of business combinations. All of the goodwill recorded in conjunction with business combinations completed after June 30, 2001 is expected to be deductible for tax purposes.

Covenants not to compete relating to business combinations completed after June 30, 2001 have a weighted-average life of 4.9 years. Amortization expense related to the covenants amounts to \$1,336,000 for the six months ended June 30, 2002. Estimated amortization expense for each of the fiscal years ending December 31, is presented below:

(DOLLARS IN THOUSANDS)	FOR THE YEAR ENDING DECEMBER 31,
-----	-----
2002.....	\$ 2,303
2003.....	1,597
2004.....	1,148
2005.....	523
2006.....	303
2007.....	27

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

NOTE F - LONG-TERM DEBT

Apria's credit agreement with Bank of America and a syndicate of lenders was amended and restated effective June 7, 2002. The amendment extended the maturity date, reduced the applicable interest rate margins and modified the repayment schedule for the company's \$175,000,000 six-year term loan. The term loan, which was amended to mature in seven years, had a balance of \$173,687,500 at June 30, 2002. It is now repayable in 21 remaining consecutive quarterly installments of \$437,500 each, followed by three consecutive quarterly installments of \$41,125,000 each, and a final payment of \$41,125,000 due on July 20, 2008.

Interest rates on outstanding balances under the credit agreement are determined by adding a margin to the Eurodollar or base rate existing at each interest calculation date. Applicable margins for the seven-year term loan were lowered and are currently fixed at 2.0% for Eurodollar loans and at 1.0% for base rate loans.

At June 30, 2002, there were no borrowings under the revolving credit facility, outstanding letters of credit totaled \$100,000, credit available under the revolving facility was \$99,900,000, and Apria was in compliance with all of the financial covenants required by the credit agreement.

NOTE G - STOCKHOLDERS' EQUITY

For the six months ended June 30, 2002, changes to stockholders' equity are comprised of the following amounts:

(DOLLARS IN THOUSANDS)

Net income.....	\$ 49,153
Proceeds from the exercise of stock options.....	12,486
Tax benefit related to the exercise of stock options.....	7,161
Other comprehensive loss, net of taxes.....	(277)
Repurchased common shares held in treasury.....	(21,780)

	\$ 46,743
	=====

For the six months ended June 30, 2002, net income and comprehensive income differed by \$277,000 which is attributable to unrealized losses on two interest rate swap agreements. There was no difference between net income and comprehensive income for the same period of the previous year.

Apria plans to repurchase up to \$35,000,000 worth of its outstanding common stock during this calendar year. Depending on market conditions and other factors, repurchases will be made in open market transactions over the next two quarters. The company repurchased 1,004,800 shares for \$21,780,000, during the six-month period ended June 30, 2002.

NOTE H - INCOME TAXES

Income taxes for the six months ended June 30, 2002 and 2001 have been provided at the effective tax rates expected to be applicable for the respective year.

At December 31, 2001, Apria had federal net operating loss carryforwards of approximately \$89,000,000, expiring in varying amounts in the years 2003 through 2018, and various state net operating loss carryforwards that began to expire in 1997. Additionally, the company has an alternative minimum tax credit

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

carryforward of approximately \$7,600,000. As a result of an ownership change in 1992 that met specified criteria of Section 382 of the Internal Revenue Code, future use of a portion of the federal and state operating loss carryforwards generated prior to 1992 are each limited to approximately \$5,000,000 per year. Because of the annual limitation, approximately \$57,000,000 of each of Apria's federal and state operating loss carryforwards may expire unused. The net operating loss carryforward amount in the related deferred tax asset excludes such amount. In 2002, for federal tax purposes, the company expects to utilize its entire net operating loss carryforward amount not subject to limitation.

NOTE I - COMMITMENTS AND CONTINGENCIES

Apria and certain of its present and former officers and/or directors are defendants in a class action lawsuit, In Re Apria Healthcare Group Securities Litigation, filed in the U.S. District Court for the Central District of California, Southern Division (Case No. SACV98-217 GLT). This case is a consolidation of three similar class actions filed in March and April, 1998. The consolidated amended class action complaint purports to establish a class of plaintiff shareholders who purchased Apria's common stock between May 22, 1995 and January 20, 1998. No class has been certified at this time. The complaint alleges, among other things, that the defendants made false and/or misleading public statements regarding Apria and its financial condition in violation of federal securities laws. The complaint seeks compensatory and punitive damages as well as other relief.

Two similar class actions were filed during July 1998 in the Superior Court for the State of California for the County of Orange: Schall v. Apria Healthcare Group Inc., et al. (Case No. 797060) and Thompson v. Apria Healthcare Group Inc., et al. (Case No. 797580). These two actions were consolidated by a court order dated October 22, 1998 (Master Case No. 797060). On June 14, 1999, the plaintiffs filed a consolidated amended class action complaint asserting claims founded on state law and on Sections 11 and 12(2) of the 1933 Securities Act.

Following a series of settlement discussions, the parties reached in early 2002 a tentative agreement to settle both the consolidated federal and state class actions described above for a total of \$42 million. In June of this year, final agreement was reached on all agreements needed to effectuate that settlement. Under the terms of the settlement, Apria has paid \$1 million and its insurance carriers have paid \$41 million into a settlement escrow account. Apria has also agreed to provide various indemnities to certain current and former Apria officers and directors who would be entitled to receive such indemnification under applicable law. A hearing to confirm the settlement as reasonable and fair to the settlement class has been set for August 20, 2002, before the Orange County Superior Court. Apria cannot provide any assurance that the Court ultimately will approve the settlement as reasonable and fair to the settlement class. However, in the opinion of Apria's management, the ultimate disposition of these class actions will not have a material adverse effect on Apria's results of operations or financial condition.

Apria and its former Chief Executive Officer are also defendants in a class action lawsuit, J.E.B. Capital Partners, LP v. Apria Healthcare Group Inc. and Philip L. Carter, filed on August 27, 2001 in the U.S. District Court for the Central District of California, Southern Division (Case No. SACV01-813 GLT). Among other things, the complaint alleges that the defendants made false and/or misleading public statements by not announcing until July 16, 2001 the amount of potential damages asserted by the U.S. Attorney's office in Los Angeles and counsel for the plaintiffs in the qui tam actions referred to below. The defendants' motion to dismiss the complaint was granted with leave to amend on June 14, 2002. Plaintiff has elected not to amend its complaint, but filed a notice of appeal on July 15, 2002. Apria believes that it has meritorious defenses to the plaintiff's claims and it intends to vigorously defend itself.

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

In the opinion of Apria's management, the ultimate disposition of this class action will not have a material adverse effect on Apria's results of operations or financial condition.

As previously reported, since mid-1998 Apria has been the subject of investigations conducted by several U.S. Attorneys' offices and the U.S. Department of Health and Human Services. These investigations concern the documentation supporting Apria's billing for services provided to patients whose healthcare costs are paid by Medicare and other federal programs. Apria is cooperating with the government in connection with these investigations and is responding to various document requests and subpoenas. A criminal investigation conducted by the U.S. Attorney's office in Sacramento was closed in mid-1999 with no charges being filed. Potential claims resulting from an investigation by the U.S. Attorney's office in San Diego were settled in mid-2001 in exchange for a payment by Apria of \$95,000.

Apria has been informed by the U.S. Attorney's office in Los Angeles that the investigation being conducted by that office is the result of civil qui tam litigation filed on behalf of the government against Apria. The complaints in the litigation are under seal, however, and the government has not informed Apria of either the identities of the plaintiffs, the court or courts where the proceedings are pending, the date or dates instituted or the factual bases alleged to underlie the proceedings. To date, the U.S. Attorney's office has not informed Apria of any decision to intervene in the qui tam actions; however, it could reach a decision with respect to intervention at any time.

On July 12, 2001, government representatives and counsel for the plaintiffs in the qui tam actions asserted that, by a process of extrapolation from a sample of 300 patient files to all of Apria's billings to the federal government during the three-and-one-half year sample period, Apria could be liable to the government under the False Claims Act for more than \$9 billion, consisting of extrapolated overpayment liability, plus treble damages and penalties of up to \$10,000 for each allegedly false claim derived from the extrapolation.

Apria has acknowledged that there may be errors and omissions in supporting documentation affecting a portion of its billings. However, it considers the assertions and amounts described in the preceding paragraph to be unsupported both legally and factually and believes that most of the alleged documentation errors and omissions should not give rise to any liability, for overpayment refunds or otherwise. Accordingly, Apria believes that the claims asserted are unwarranted and that it is in a position to assert numerous meritorious defenses. Nevertheless, Apria cannot provide any assurances as to the outcome of these proceedings. Management cannot estimate the possible loss or range of loss that may result from these proceedings and therefore has not recorded any related accruals.

If a judge, jury or administrative agency were to determine that false claims were submitted to federal healthcare programs or that there were significant overpayments by the government, Apria could face civil and administrative claims for refunds, sanctions and penalties for amounts that would be highly material to its business, results of operations and financial condition, including the exclusion of Apria from participation in federal healthcare programs.

Apria is also engaged in the defense of certain claims and lawsuits arising out of the ordinary course and conduct of its business, the outcomes of which are not determinable at this time. Apria has insurance policies covering such potential losses where such coverage is cost effective. In the opinion of management, any liability that might be incurred by Apria upon the resolution of these claims and lawsuits will not, in the aggregate, have a material adverse effect on Apria's results of operations or financial condition.

NOTE J - PER SHARE AMOUNTS

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

The following table sets forth the computation of basic and diluted per share amounts:

(IN THOUSANDS, EXCEPT PER SHARE DATA)	THREE MONTHS ENDED JUNE 30,		SIX MONTHS JUNE 30
	2002	2001	2002
NUMERATOR:			
Net income	\$26,158	\$17,247	\$49,153
Numerator for basic and diluted per share amounts - income available to common stockholders	\$26,158	\$17,247	\$49,153
DENOMINATOR:			
Denominator for basic per share amounts - weighted average shares	54,434	53,748	54,363
Effect of dilutive securities:			
Employee stock options - dilutive potential common shares	986	2,000	1,156
Denominator for diluted per share amounts - adjusted weighted average shares	55,420	55,748	55,519
Basic net income per common share	\$ 0.48	\$ 0.32	\$ 0.90
Diluted net income per common share	\$ 0.47	\$ 0.31	\$ 0.89
Employee stock options excluded from the computation of diluted per share amounts:			
Shares for which exercise price exceeds average market price of common stock	1,503	1,815	2,572
Average exercise price per share that exceeds average market price of common stock	\$ 26.39	\$ 27.12	\$ 25.40

CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Apria's business is subject to a number of risks which are partly or entirely beyond the company's control. The company has described certain of those risks in its Form 10-K for the fiscal year ended December 31, 2001, as filed with the Securities and Exchange Commission on April 1, 2002. This report may be used for purposes of the Private Securities Litigation Reform Act of 1995 as a readily available document containing meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in any forward-looking statements the company may make from time to time. Those risks include:

- trends and developments affecting the collectibility of accounts

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

- receivable;
- the effectiveness of the company's operating systems and controls;
- healthcare reform and the effect of federal and state healthcare regulations;
- government legislative and budget developments which could affect reimbursement levels for products and services provided by Apria;
- the ongoing government investigations regarding patients covered by Medicare and other federal programs;
- pricing pressures from large payors; and
- the successful implementation of the company's acquisition strategy and integration of acquired businesses.

In addition, the terrorist attacks of September 11, 2001 and the military and security activities which followed, their impacts on the United States economy and government spending priorities, and the effects of any further such developments pose risks and uncertainties to all U.S.-based businesses, including Apria. Among other things, deficit spending by the government as the result of adverse developments in the economy and costs of the government's response to the terrorist attacks could lead to the increased pressure to reduce government expenditures for other purposes, including governmentally-funded programs such as Medicare.

=====

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Apria operates in the home healthcare segment of the healthcare industry and provides services in the home respiratory therapy, home infusion therapy and home medical equipment areas. In all three lines, Apria provides patients with a variety of clinical services and related products and supplies, most of which are prescribed by a physician as part of a care plan. Apria provides these services to patients in the home throughout the United States through approximately 400 branch locations.

CRITICAL ACCOUNTING POLICIES. Apria's management considers the accounting policies that govern revenue recognition and the determination of the net realizable value of accounts receivable to be the most critical in relation to the company's consolidated financial statements. These policies require management's most complex and subjective judgments. Other accounting policies requiring significant judgment are those related to goodwill and income taxes. These policies are presented in detail in Apria's 2001 Form 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.

SEGMENT REPORTING. Apria's branch locations are organized into geographic regions. Each region consists of a number of branches and a regional office that provides key support services, such as billing, purchasing, patient service equipment maintenance, repair and warehousing. Management evaluates operating results on a geographic basis, and therefore views each region as an operating segment. All regions provide the same products and services, including respiratory therapy, infusion therapy and home medical equipment and supplies. For financial reporting purposes, all the company's operating segments are aggregated into one reportable segment in accordance with the aggregation criteria in paragraph 17 of Statement of Financial Accounting Standards ("SFAS") No. 131, "Disclosures about Segments of an Enterprise and Related Information."

RECENT ACCOUNTING PRONOUNCEMENTS. Effective January 1, 2002, Apria adopted SFAS No. 142, "Goodwill and Other Intangible Assets", in its entirety. SFAS No. 142 addresses the financial accounting and reporting for goodwill and other intangible assets. The statement provides that goodwill or other intangible assets with indefinite lives will no longer be amortized, but shall be tested for impairment annually, or more frequently if circumstances indicate potential impairment. Upon adoption, a transitional goodwill impairment test must be

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

performed. The test is conducted at the "reporting unit" level and compares each reporting unit's fair value to its carrying value. Apria's management has determined that its geographic regions are reporting units under SFAS No. 142. Apria's transitional goodwill impairment test utilized a discounted cash flow approach in determining fair value, which was further tested by a multiple of earnings approach. The transitional test has been completed; no goodwill impairment is indicated at any of Apria's reporting units. See "Amortization of Goodwill and Intangible Assets."

Effective January 1, 2002 Apria adopted SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." SFAS No. 144 requires that one accounting model be used for long-lived assets to be disposed of by sale. Discontinued operations will be measured similarly to other long-lived assets classified as held for sale at the lower of its carrying amount or fair value less cost to sell. Future operating losses will no longer be recognized before they occur. SFAS No. 144 also broadens the presentation of discontinued operations to include a component of an entity when operations and cash flows can be clearly distinguished, and establishes criteria to determine when a long-lived asset is held for sale. Adoption of this statement did not have a material effect on Apria's financial statements.

RESULTS OF OPERATIONS

NET REVENUES. Net revenues were \$310.4 million and \$611.8 million in the second quarter and first six months of 2002, respectively, compared to \$283.5 million and \$554.8 million for the corresponding periods in 2001. This represents increases of 9.5% and 10.3% for the three and six month periods, respectively. The growth is due to volume increases, new contracts with regional and national payors, the acquisition of complementary businesses and price increases in certain managed care agreements.

Apria's acquisition strategy generally results in the rapid integration of acquired businesses into existing operating locations. This limits management's ability to separately track the amount of revenue generated by an acquired business. Estimating the revenue contribution from acquisitions therefore requires certain assumptions. Based on its analyses, Apria's management estimates that approximately one-third of the revenue growth between the six month periods presented was derived from acquisitions.

The following table sets forth a summary of net revenues by service line:

(DOLLARS IN THOUSANDS)	THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED	
	2002		2001		2002	
	\$	%	\$	%	\$	%
Respiratory therapy.....	\$205,263	66.1%	\$185,081	65.3%	\$408,495	66.1%
Infusion therapy.....	57,636	18.6%	54,874	19.4%	111,419	18.6%
HME/other.....	47,526	15.3%	43,525	15.3%	91,856	15.3%
Total net revenues	\$310,425	100.0%	\$283,480	100.0%	\$611,770	100.0%

Home Respiratory Therapy. Respiratory therapy revenues are derived primarily from the provision of oxygen systems, home ventilators, sleep apnea equipment, nebulizers, respiratory medications and related services. The respiratory therapy service line increased by 10.9% and 12.4% in the second

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

quarter and first half of 2002, respectively, as compared to the same periods in 2001. Apria's focus on the acquisition of respiratory therapy businesses contributed to this growth.

Home Infusion Therapy. The infusion therapy service line involves the administration of a drug or nutrient directly into the body intravenously through a needle or catheter. Examples include: parenteral nutrition, anti-infectives, pain management, chemotherapy and other medications and related services. The infusion line also includes enteral nutrition, which is the administration of nutrients directly into the gastrointestinal tract through a feeding tube. Infusion therapy revenues increased by 5.0% and 3.9% in the second quarter and first six months of 2002, respectively, when compared to the corresponding periods in 2001. For the six month period in 2002, the growth percentage reflects the effect of a 13.9% increase in enteral nutrition attributable to a renewed focus on this product, resulting from a program (initiated in mid-2001) that centralized the enteral intake and distribution functions at the regional level. Offsetting this was a 1.2% decline in the remaining infusion line, due in part to eliminating certain product offerings within a large contract.

Home Medical Equipment/Other. Home medical equipment/other revenues are derived from the provision of patient safety items, ambulatory and patient room equipment. Home medical equipment/other revenues increased by 9.2% and 9.1% in the second quarter and first six months of 2002, respectively, as compared to the same periods in 2001. The increase between periods is partially due to the fact that the full Medicare cost of living adjustment for certain durable medical equipment products and services that had been frozen since 1998 pursuant to the Balanced Budget Act of 1997 was restored in 2001. Substantially all of this adjustment was provided through a transitional allowance applied to amounts reimbursed during the second half of the year. The 2002 reimbursement amounts incorporate the 2001 adjustments as if they had been applied evenly throughout the year. Medicare reimbursement amounts for 2002 include only minimal increases significantly below the cost of living rate.

Revenue Recognition and Certain Concentrations. Revenues are recognized on the date services and related products are provided to patients and are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare and Medicaid. Due to the nature of the industry and the reimbursement environment in which Apria operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available, which could have an impact on the consolidated financial statements.

Approximately 33% of Apria's revenues are reimbursed under arrangements with Medicare and Medicaid. No other third-party payor represents 10% or more of the company's revenues. The majority of the company's revenues are derived from fees charged for patient care under fee-for-service arrangements. Revenues derived from capitation arrangements represent less than 10% of total net revenues for all periods presented.

Medicare and Medicaid Reimbursement. The Balanced Budget Act of 1997 significantly reduced the Medicare reimbursement rates for home oxygen therapy and included other provisions that have impacted or may impact reimbursement rates in the future, such as potential reimbursement reductions under an inherent reasonableness procedure and competitive bidding. Also currently at issue is the potential adoption of an alternative pricing methodology for certain drugs and biologicals. These issues are discussed in detail in Apria's 2001 Form 10-K.

In June 2002, the U.S. House of Representatives passed the Medicare

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

Modernization and Prescription Drug Act of 2002. The bill provides for a nationwide competitive bidding program for an as-yet-undetermined list of durable medical equipment ("DME") items covered by Medicare Part B. In July 2002, the U.S. Senate failed to pass a Medicare prescription drug benefit. None of the Senate proposals contained Medicare "provider adjustments" such as competitive bidding for DME. The Senate is likely to take up these provider adjustment issues in the third quarter, but it is unclear at the present time whether the Senate will include competitive bidding for DME or other issues of interest to Apria in such legislation. It is also unclear whether competitive bidding or other issues of interest to Apria will be included in the conference report on Medicare provider adjustments that the House and Senate negotiators may finally agree upon before adjournment.

GROSS PROFIT. Gross margins for both the second quarter of 2002 and the first half of 2002 were 72.8% compared to 73.3% and 72.6% for the corresponding periods in the prior year. The higher margin in the second quarter of 2001 was due in part to a retroactive price increase of a managed care contract .

PROVISION FOR DOUBTFUL ACCOUNTS. The provision for doubtful accounts was 3.7% of net revenues for the second quarter of 2002 and 3.8% for the first six months of 2002 compared to 3.9% and 3.5% for the corresponding periods in 2001. The provision for doubtful accounts results from management's estimate of the net realizable value of accounts receivable after considering actual write-offs of specific receivables. The increase in the provision between the six month periods can be attributed to the increase in accounts receivable in the first quarter of 2002 due mainly to two large fourth quarter acquisitions. Such acquisitions result in integrating a significant amount of patient information into Apria's information systems and document files which can delay the billing and collection process. Also contributing to the accounts receivable growth in the first quarter are the following factors that are typical with the start of a new calendar year: (1) patient payor and/or benefit changes that can slow the billing and collection process as the new payor information is obtained; and (2) patient deductible requirements that can also slow the collection process. These new-year factors were also present in 2001, however the magnitude was greater in 2002 due to revenue growth and the fourth quarter acquisitions. The rate of accounts receivable increase declined in the second quarter of 2002. See "Accounts Receivable - Evaluation of Net Realizable Value."

SELLING, DISTRIBUTION AND ADMINISTRATIVE. Selling, distribution and administrative expenses are comprised of expenses incurred in direct support of operations and those associated with administrative functions. Expenses incurred by the operating locations include salaries and other expenses in the following functional areas: selling, distribution, clinical, intake, reimbursement, warehousing and repair. Many of these operating costs are directly variable with revenue growth patterns. Certain expenses, such as facility lease and fuel costs, are also very sensitive to market-driven price fluctuations. The administrative expenses include overhead costs incurred by the operating locations and corporate support functions. These expenses do not vary as closely with revenue growth as do the operating costs. Selling, distribution and administrative expenses, expressed as percentages of net revenues, were 54.1% and 54.6% for the second quarter and first half of 2002, respectively, versus 55.8% and 55.2% for the corresponding periods in 2001. In 2002, the first quarter included \$2.6 million in contract termination costs related to the departure of the former Chief Executive Officer and the second quarter included approximately \$2.2 million in merit compensation increases. Despite these additional expenses, management was able to leverage its expense structure against the revenue growth.

AMORTIZATION OF GOODWILL AND INTANGIBLE ASSETS. Amortization of intangible assets for the second quarter and the six months ended June 30, 2002 were \$665,000 and \$1.3 million, respectively, compared to \$3.1 million and \$6.0 million for the same periods last year (which included goodwill amortization).

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

Upon adoption of SFAS No. 142 on January 1, 2002, goodwill amortization ceased. Amortization of goodwill was \$2.5 million for the second quarter and \$4.7 million for the first six months of 2001. The effect of adding this amount back as though SFAS No. 142 were adopted at the beginning of the prior year would have been increases in net income of \$1.6 million and \$2.9 million and increases in diluted income per common share of \$0.03 and \$0.05 for the second quarter and first six months of 2001, respectively. See "Recent Accounting Pronouncements", "Business Combinations" and Note C to the Condensed Consolidated Financial Statements.

INTEREST EXPENSE. Interest expense was \$4.0 million for the second quarter of 2002, down from \$8.0 million in the second quarter of 2001. For the six months ended June 30, 2002 interest expense was \$8.1 million compared to \$16.4 million in the same period in 2001. The significant decrease between the periods is due to a number of factors. From June 30, 2001 to June 30, 2002, long-term debt decreased by \$52.1 million. The July 2001 refinancing replaced the 9 1/2% senior subordinated notes with debt at significantly more favorable interest rates and resulted in lower rates on the bank loans. In connection with the refinancing, deferred debt issuance costs on the 9 1/2% notes and former bank debt were written off; the issuance costs incurred upon refinancing resulted in a lower monthly amortization expense. Also, the June 2002 credit agreement amendment included a reduction in the applicable interest rate margin for the \$175 million term loan. Finally, the dramatic decreases in market-driven interest rates over the course of 2001 contributed to the overall decrease in Apria's interest expense. See "Long-Term Debt."

INCOME TAXES. Income taxes for the six months ended June 30, 2002 and in the corresponding period of 2001, have been provided at the effective tax rates expected to be applicable for the respective year.

At December 31, 2001, Apria had federal net operating loss carryforwards of approximately \$89 million, expiring in varying amounts in the years 2003 through 2018 and various state net operating loss carryforwards that began to expire in 1997. Additionally, the company has an alternative minimum tax credit carryforward of approximately \$7.6 million. As a result of an ownership change in 1992 that met specified criteria of Section 382 of the Internal Revenue Code, future use of a portion of the federal and state operating loss carryforwards generated prior to 1992 are each limited to approximately \$5 million per year. Because of the annual limitation, approximately \$57 million of each of Apria's federal and state operating loss carryforwards may expire unused. The net operating loss carryforward amount in the related deferred tax asset excludes such amount. In 2002, for federal tax purposes, the company expects to utilize its entire net operating loss carryforward not subject to limitation.

LIQUIDITY AND CAPITAL RESOURCES

Apria's principal source of liquidity is its operating cash flow, which is supplemented by a \$100 million revolving credit facility. Apria's ability to generate operating cash flows in excess of its operating needs has afforded it the ability, among other things, to pursue its acquisition strategy and fund patient service equipment expenditures to support revenue growth. Apria's management believes that its operating cash flow and revolving credit line will continue to be sufficient to fund its operations and growth strategies. However, sustaining the current cash flow levels is dependent on many factors, some of which are not within Apria's control, such as government reimbursement levels and the financial health of its payors.

CASH FLOW. Cash provided by operating activities was \$107.7 million in the first six months of 2002 compared with \$101.2 million in the corresponding period in 2001. The increase between periods in net income (before items not requiring cash) was partially offset by the increase in accounts receivable and

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

increases in payments against accounts payable and other expense accruals.

Cash used in investing activities decreased to \$72.7 million for the first half of 2002 compared to \$101.7 million during the same period last year. The decrease in cash used is attributable to the difference in acquisition activity between the periods and a decrease in patient service and other equipment purchases.

Cash used in financing activities was \$27.3 million during the first six months of 2002 compared to \$10.3 million provided by financing activities during the same period last year. The difference is mainly due to the stock repurchases effected in the 2002 period. See "Treasury Stock."

CONTRACTUAL CASH OBLIGATIONS. The following table summarizes Apria's long term cash payment obligations to which the company is contractually bound (the years presented below represent twelve-month rolling periods ending June 30):

(DOLLARS IN MILLIONS)	YEAR 1	YEAR 2	YEAR 3	YEAR 4	YEAR 5
Term loans.....	\$ 25	\$ 26	\$ 28	\$ 29	\$ 9
Capitalized lease obligations.....	3	2	2	-	-
Operating leases.....	53	44	35	28	16
Deferred acquisition payments.....	6				
	----	----	----	----	----
Total contractual obligations.....	\$ 87	\$ 72	\$ 65	\$ 57	\$ 25
	====	====	====	====	====

ACCOUNTS RECEIVABLE. Accounts receivable before allowance for doubtful accounts increased to \$209.0 million at June 30, 2002 from \$194.2 million at December 31, 2001, which is attributable to the revenue increases. Days sales outstanding (calculated as of each period end by dividing accounts receivable, less allowance for doubtful accounts, by the 90-day rolling average of net revenues) were 51 at June 30, 2002, and 50 at December 31, 2001. Accounts aged in excess of 180 days decreased to 17.7% at June 30, 2002 from 19.8% at December 31, 2001. See "Provision for Doubtful Accounts."

Evaluation of Net Realizable Value. Management performs various analyses to evaluate accounts receivable balances to ensure that recorded amounts reflect estimated net realizable value. Management applies specified percentages to the accounts receivable aging to estimate the amount that will ultimately be uncollectible and therefore should be reserved. The percentages are increased as the accounts age; accounts aged in excess of 360 days are reserved at 100%. Management establishes and monitors these percentages through extensive analyses of historical realization data, accounts receivable aging trends, other operating trends, the extent of contracted business and business combinations. Also considered are relevant business conditions, such as governmental and managed care payor claims processing procedures and system changes. If indicated by such analyses, management may periodically adjust the uncollectible estimate and corresponding percentages. Further, focused reviews of certain large and/or problematic payors are performed to determine if additional reserves are necessary.

Unbilled Receivables. Included in accounts receivable are earned but unbilled receivables of \$30.0 million and \$26.9 million at June 30, 2002 and December 31, 2001, respectively. Delays, ranging from a day up to several weeks, between the date of service and billing can occur due to delays in obtaining certain required payor-specific documentation from internal and external sources. Earned but unbilled receivables are aged from date of service and are considered in Apria's analysis of net realizable value. The increase is partially due to acquisitions effected late in 2001 and in 2002. The

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

time-consuming processes of converting patient files onto Apria's systems and obtaining provider numbers from government payors routinely delay billing of the newly acquired business.

INVENTORIES AND PATIENT SERVICE EQUIPMENT. Inventories consist primarily of pharmaceuticals and disposable articles used in conjunction with patient service equipment. Patient service equipment consists of respiratory and home medical equipment that is provided to in-home patients for the course of their care plan and subsequently returned to Apria for reuse. Continued revenue growth is directly dependent on Apria's ability to fund its inventory and patient service equipment requirements.

LONG-TERM DEBT. Apria's credit agreement with Bank of America and a syndicate of lenders was amended and restated effective June 7, 2002. The amendment extended the maturity date, reduced the applicable interest rate margins and modified the repayment schedule for the company's \$175 million six-year term loan. The term loan, which was amended to mature in seven years, had a balance of \$173.7 million at June 30, 2002. It is now repayable in 21 remaining consecutive quarterly installments of \$437,500 each, followed by three consecutive quarterly installments of \$41.1 million each, and a final payment of \$41.1 million due on July 20, 2008.

Interest rates on outstanding balances under the credit agreement are determined by adding a margin to the Eurodollar or base rate existing at each interest calculation date. Applicable margins for the seven-year term loan were lowered to 2.0% for Eurodollar loans and 1.0% for base rate loans.

On June 30, 2002, total borrowings under the credit agreement were \$282.2 million. Outstanding letters of credit totaled \$100,000 and credit available under the revolving facility was \$99.9 million. At June 30, 2002, the company was in compliance with all of the financial covenants required by the credit agreement.

Hedging Activities. Apria is exposed to interest rate fluctuations on its underlying variable rate long-term debt. Apria's policy for managing interest rate risk is to evaluate and monitor all available relevant information, including but not limited to, the structure of its interest-bearing assets and liabilities, historical interest rate trends and interest rate forecasts published by major financial institutions. The tools Apria may utilize to moderate its exposure to fluctuations in the relevant interest rate indices include, but are not limited to: (1) strategic determination of repricing periods and related principal amounts, and (2) derivative financial instruments such as interest rate swap agreements, caps or collars. Apria does not use derivative financial instruments for trading or other speculative purposes.

Apria has two interest rate swap agreements with a total notional amount of \$100 million that fix its LIBOR-based variable rate debt at 2.58% (before the applicable margin). The swap agreements terminate March 2003. The swaps are being accounted for as cash flow hedges under SFAS No. 133. Accordingly, the difference between the interest received and interest paid is reflected as an adjustment to interest expense. For the first six months of 2002, Apria paid a net settlement amount of \$289,000. At June 30, 2002, the swap agreements are reflected in the accompanying consolidated balance sheet in other accrued liabilities at their fair value of \$401,000. Unrealized losses on the fair value of the swap agreements are reflected, net of taxes, in other comprehensive loss.

Apria does not anticipate losses due to counterparty nonperformance, as its counterparty to the swap agreements is a nationally-recognized financial institution with a strong credit rating.

TREASURY STOCK. Apria plans to repurchase up to \$35 million worth of its outstanding common stock during this calendar year. Depending on market

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

conditions and other considerations, repurchases will be made from time to time in open market transactions. During the first six months of 2002, Apria repurchased 1,004,800 shares for \$21.8 million. All repurchased common shares are being held in treasury. Apria's credit agreement limits common stock repurchases to \$35 million in any fiscal year and \$100 million in the aggregate over the term of the agreement.

BUSINESS COMBINATIONS. Pursuant to one of its primary growth strategies, Apria periodically acquires complementary businesses in specific geographic markets. These transactions are accounted for as purchases and the results of operations of the acquired companies are included in the accompanying consolidated income statements from the dates of acquisition. Effective with the adoption of SFAS No. 142, goodwill is no longer being amortized. Covenants not to compete are being amortized over the life of the respective agreements.

The aggregate consideration for acquisitions that closed during the first half of 2002 was \$18.4 million. Allocation of this amount includes \$15.7 million to goodwill, \$581,000 to intangible assets and \$1.7 million to patient service equipment. During the first half of 2001, the aggregate consideration for acquisitions was \$37 million. Cash paid for acquisitions, which includes amounts deferred from prior year acquisitions, totaled \$15.7 million and \$35 million in the first six months of 2002 and 2001, respectively.

The success of Apria's acquisition strategy is directly dependent on Apria's ability to maintain and/or generate sufficient liquidity to fund such purchases and on the company's ability to integrate the acquired operations successfully.

FEDERAL INVESTIGATIONS. As previously reported, since mid-1998 Apria has been the subject of investigations conducted by several U.S. Attorneys' offices and the U.S. Department of Health and Human Services. These investigations concern the documentation supporting Apria's billing for services provided to patients whose healthcare costs are paid by Medicare and other federal programs. Apria is cooperating with the government in connection with these investigations and is responding to various document requests and subpoenas. A criminal investigation conducted by the U.S. Attorney's office in Sacramento was closed in mid-1999 with no charges being filed. Potential claims resulting from an investigation by the U.S. Attorney's office in San Diego were settled in mid-2001 in exchange for a payment by Apria of \$95,000.

Apria has been informed by the U.S. Attorney's office in Los Angeles that the investigation being conducted by that office is the result of civil qui tam litigation filed on behalf of the government against Apria. The complaints in the litigation are under seal, however, and the government has not informed Apria of either the identities of the plaintiffs, the court or courts where the proceedings are pending, the date or dates instituted or the factual bases alleged to underlie the proceedings. To date, the U.S. Attorney's office has not informed Apria of any decision to intervene in the qui tam actions; however, it could reach a decision with respect to intervention at any time.

On July 12, 2001, government representatives and counsel for the plaintiffs in the qui tam actions asserted that, by a process of extrapolation from a sample of 300 patient files to all of Apria's billings to the federal government during the three-and-one-half year sample period, Apria could be liable to the government under the False Claims Act for more than \$9 billion, consisting of extrapolated overpayment liability, plus treble damages and penalties of up to \$10,000 for each allegedly false claim derived from the extrapolation.

Apria has acknowledged that there may be errors and omissions in supporting documentation affecting a portion of its billings. However, it considers the assertions and amounts described in the preceding paragraph to be unsupported both legally and factually and believes that most of the alleged documentation

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

errors and omissions should not give rise to any liability, for overpayment refunds or otherwise. Accordingly, Apria believes that the claims asserted are unwarranted and that it is in a position to assert numerous meritorious defenses. Nevertheless, Apria cannot provide any assurances as to the outcome of these proceedings. Management cannot estimate the possible loss or range of loss that may result from these proceedings and therefore has not recorded any related accruals.

If a judge, jury or administrative agency were to determine that false claims were submitted to federal healthcare programs or that there were significant overpayments by the government, Apria could face civil and administrative claims for refunds, sanctions and penalties for amounts that would be highly material to its business, results of operations and financial condition, including the exclusion of Apria from participation in federal healthcare programs.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Apria is exposed to interest rate fluctuations on its underlying variable rate long-term debt. Apria utilizes interest rate swap agreements to moderate such exposure. Apria does not use derivative financial instruments for trading or other speculative purposes.

At June 30, 2002, Apria's term loan borrowings totaled \$282.2 million. The bank credit agreement governing the term loans provides interest rate options based on the following indices: Federal Funds Rate, Prime Rate or LIBOR. All such interest rate options are subject to the application of an interest margin as specified in the bank credit agreement. At June 30, 2002, all of Apria's outstanding term debt was tied to LIBOR. Apria has two interest rate swap agreements with a total notional amount of \$100 million that fix its LIBOR-based debt at 2.58% (before application of the interest margin). Both agreements expire March 2003.

Based on the term debt outstanding and the swap agreements in place at June 30, 2002, a 100 basis point change in LIBOR would increase or decrease Apria's annual cash flow and pretax earnings by approximately \$1.8 million.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Apria and certain of its present and former officers and/or directors are defendants in a class action lawsuit, In Re Apria Healthcare Group Securities Litigation, filed in the U.S. District Court for the Central District of California, Southern Division (Case No. SACV98-217 GLT). This case is a consolidation of three similar class actions filed in March and April, 1998. The consolidated amended class action complaint purports to establish a class of plaintiff shareholders who purchased Apria's common stock between May 22, 1995 and January 20, 1998. No class has been certified at this time. The complaint alleges, among other things, that the defendants made false and/or misleading public statements regarding Apria and its financial condition in violation of federal securities laws. The complaint seeks compensatory and punitive damages as well as other relief.

Two similar class actions were filed during July 1998 in the Superior Court for the State of California for the County of Orange: Schall v. Apria Healthcare Group Inc., et al. (Case No. 797060) and Thompson v. Apria Healthcare Group Inc., et al. (Case No. 797580).

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

These two actions were consolidated by a court order dated October 22, 1998 (Master Case No. 797060). On June 14, 1999, the plaintiffs filed a consolidated amended class action complaint asserting claims founded on state law and on Sections 11 and 12(2) of the 1933 Securities Act.

Following a series of settlement discussions, the parties reached in early 2002 a tentative agreement to settle both the consolidated federal and state class actions described above for a total of \$42 million. In June of this year, final agreement was reached on all agreements needed to effectuate that settlement. Under the terms of the settlement, Apria has paid \$1 million and its insurance carriers have paid \$41 million into a settlement escrow account. Apria has also agreed to provide various indemnities to certain current and former Apria officers and directors who would be entitled to receive such indemnification under applicable law. A hearing to confirm the settlement as reasonable and fair to the settlement class has been set for August 20, 2002, before the Orange County Superior Court. Apria cannot provide any assurance that the Court ultimately will approve the settlement as reasonable and fair to the settlement class. However, in the opinion of Apria's management, the ultimate disposition of these class actions will not have a material adverse effect on Apria's results of operations or financial condition.

Apria and its former Chief Executive Officer are also defendants in a class action lawsuit, J.E.B. Capital Partners, LP v. Apria Healthcare Group Inc. and Philip L. Carter, filed on August 27, 2001 in the U.S. District Court for the Central District of California, Southern Division (Case No. SACV01-813 GLT). Among other things, the complaint alleges that the defendants made false and/or misleading public statements by not announcing until July 16, 2001 the amount of potential damages asserted by the U.S. Attorney's office in Los Angeles and counsel for the plaintiffs in the qui tam actions referred to below. The defendants' motion to dismiss the complaint was granted with leave to amend on June 14, 2002. Plaintiff has elected not to amend its complaint, but filed a notice of appeal on July 15, 2002. Apria believes that it has meritorious defenses to the plaintiff's claims and it intends to vigorously defend itself. In the opinion of Apria's management, the ultimate disposition of this class action will not have a material adverse effect on Apria's results of operations or financial condition.

As previously reported, since mid-1998 Apria has been the subject of investigations conducted by several U.S. Attorneys' offices and the U.S. Department of Health and Human Services. These investigations concern the documentation supporting Apria's billing for services provided to patients whose healthcare costs are paid by Medicare and other federal programs. Apria is cooperating with the government in connection with these investigations and is responding to various document requests and subpoenas. A criminal investigation conducted by the U.S. Attorney's office in Sacramento was closed in mid-1999 with no charges being filed. Potential claims resulting from an investigation by the U.S. Attorney's office in San Diego were settled in mid-2001 in exchange for a payment by Apria of \$95,000.

Apria has been informed by the U.S. Attorney's office in Los Angeles that the investigation being conducted by that office is the result of civil qui tam litigation filed on behalf of the government against Apria. The complaints in the litigation are under seal, however, and the government has not informed Apria of either the identities of the plaintiffs, the court or courts where the proceedings are pending, the date or dates instituted or the factual

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

bases alleged to underlie the proceedings. To date, the U.S. Attorney's office has not informed Apria of any decision to intervene in the qui tam actions; however, it could reach a decision with respect to intervention at any time.

On July 12, 2001, government representatives and counsel for the plaintiffs in the qui tam actions asserted that, by a process of extrapolation from a sample of 300 patient files to all of Apria's billings to the federal government during the three-and-one-half year sample period, Apria could be liable to the government under the False Claims Act for more than \$9 billion, consisting of extrapolated overpayment liability, plus treble damages and penalties of up to \$10,000 for each allegedly false claim derived from the extrapolation.

Apria has acknowledged that there may be errors and omissions in supporting documentation affecting a portion of its billings. However, it considers the assertions and amounts described in the preceding paragraph to be unsupported both legally and factually and believes that most of the alleged documentation errors and omissions should not give rise to any liability, for overpayment refunds or otherwise. Accordingly, Apria believes that the claims asserted are unwarranted and that it is in a position to assert numerous meritorious defenses. Nevertheless, Apria cannot provide any assurances as to the outcome of these proceedings. Management cannot estimate the possible loss or range of loss that may result from these proceedings and therefore has not recorded any related accruals.

If a judge, jury or administrative agency were to determine that false claims were submitted to federal healthcare programs or that there were significant overpayments by the government, Apria could face civil and administrative claims for refunds, sanctions and penalties for amounts that would be highly material to its business, results of operations and financial condition, including the exclusion of Apria from participation in federal healthcare programs.

Apria is also engaged in the defense of certain claims and lawsuits arising out of the ordinary course and conduct of its business, the outcomes of which are not determinable at this time. Apria has insurance policies covering such potential losses where such coverage is cost effective. In the opinion of management, any liability that might be incurred by Apria upon the resolution of these claims and lawsuits will not, in the aggregate, have a material adverse effect on Apria's results of operations or financial condition.

ITEMS 2-5. NOT APPLICABLE

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits:

Exhibit Number	Reference
-----	-----
10.1	Executive Severance Agreement effective May 8, 2002 between Registrant and Anthony S. Domenico.
10.2	Third Amended and Restated Credit Agreement dated June

Edgar Filing: APRIA HEALTHCARE GROUP INC - Form 10-Q

7, 2002, among Registrant and certain of its subsidiaries, Bank of America National Association and other financial institutions party to the Credit Agreement.

99.1 Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

(b) Reports on Form 8-K:

No reports on Form 8-K were filed during the quarter for which this report is filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

APRIA HEALTHCARE GROUP INC.

Registrant

August 14, 2002

/s/ JAMES E. BAKER

James E. Baker
Chief Financial Officer
(Principal Financial and Accounting Officer)